{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:23:35Z","timestamp":1788305015858,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":73,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031121838","type":"print"},{"value":"9783031121845","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/7854_2022_327","type":"book-chapter","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:03:00Z","timestamp":1655265780000},"page":"213-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation"],"prefix":"10.1007","author":[{"given":"Matthew W.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"4","key":"327_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000468273","volume":"6","author":"FS Abuzzahab","year":"1971","unstructured":"Abuzzahab FS, Anderson BJ (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 6(4):223\u2013235. https:\/\/doi.org\/10.1159\/000468273","journal-title":"Int Pharmacopsychiatry"},{"issue":"2","key":"327_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12231-011-9152-5","volume":"65","author":"BP Akers","year":"2011","unstructured":"Akers BP, Francisco J, Piper A, Ruck CAP (2011) A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Econ Bot 65(2):121\u2013128. https:\/\/doi.org\/10.1007\/s12231-011-9152-5","journal-title":"Econ Bot"},{"issue":"11","key":"327_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1176\/ajp.131.11.1247","volume":"131","author":"BJ Albaugh","year":"1974","unstructured":"Albaugh BJ, Anderson PO (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry 131(11):1247\u20131250. https:\/\/doi.org\/10.1176\/ajp.131.11.1247","journal-title":"Am J Psychiatry"},{"issue":"52","key":"327_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.15585\/mmwr.mm6552a1","volume":"65","author":"S Babb","year":"2017","unstructured":"Babb S, Malarcher A, Schauer G, Asman K, Jamal A (2017) Quitting smoking among adults \u2013 United States, 2000\u20132015. MMWR Morb Mortal Wkly Rep 65(52):1457\u20131464. https:\/\/doi.org\/10.15585\/mmwr.mm6552a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"327_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/ajp.128.6.695","volume":"128","author":"RL Bergman","year":"1971","unstructured":"Bergman RL (1971) Navajo peyote use: its apparent safety. Am J Psychiatry 128(6):695\u2013699. https:\/\/doi.org\/10.1176\/ajp.128.6.695","journal-title":"Am J Psychiatry"},{"issue":"4","key":"327_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/15563657708988210","volume":"11","author":"K Blum","year":"1977","unstructured":"Blum K, Futterman SFL, Pascarosa P (1977) Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: possible biochemical rationale. Clin Toxicol 11(4):459\u2013472. https:\/\/doi.org\/10.3109\/15563657708988210","journal-title":"Clin Toxicol"},{"issue":"3","key":"327_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29(3):289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","journal-title":"J Psychopharmacol"},{"issue":"2","key":"327_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","volume":"235","author":"KR Bonson","year":"2018","unstructured":"Bonson KR (2018) Regulation of human research with LSD in the United States (1949-1987). Psychopharmacology 235(2):591\u2013604. https:\/\/doi.org\/10.1007\/s00213-017-4777-4","journal-title":"Psychopharmacology"},{"issue":"2","key":"327_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jama.2013.283787","volume":"311","author":"K Cahill","year":"2014","unstructured":"Cahill K, Stevens S, Lancaster T (2014) Pharmacological treatments for smoking cessation. J Am Med Assoc 311(2):193\u2013194. https:\/\/doi.org\/10.1001\/jama.2013.283787","journal-title":"J Am Med Assoc"},{"issue":"2","key":"327_CR10","first-page":"237","volume":"84","author":"JD Calabrese","year":"1997","unstructured":"Calabrese JD (1997) Spiritual healing and human development in the native American church: toward a cultural psychiatry of peyote. Psychoanal Rev 84(2):237\u2013255","journal-title":"Psychoanal Rev"},{"issue":"12","key":"327_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW et al (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278. https:\/\/doi.org\/10.1177\/0269881116662634","journal-title":"J Psychopharmacol"},{"issue":"7","key":"327_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet 3(7):619\u2013627. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet"},{"issue":"15","key":"327_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"issue":"3","key":"327_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","volume":"20","author":"N Chwelos","year":"1959","unstructured":"Chwelos N, Blewett DB, Smith CM, Hoffer A (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol 20(3):577\u2013590. https:\/\/doi.org\/10.15288\/qjsa.1959.20.577","journal-title":"Q J Stud Alcohol"},{"issue":"4","key":"327_CR15","doi-asserted-by":"publisher","first-page":"e1000058","DOI":"10.1371\/journal.pmed.1000058","volume":"6","author":"G Danaei","year":"2009","unstructured":"Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJL et al (2009) The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 6(4):e1000058. https:\/\/doi.org\/10.1371\/journal.pmed.1000058","journal-title":"PLoS Med"},{"issue":"5","key":"327_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat 78(5):481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiat"},{"issue":"3","key":"327_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/02791072.2002.10399960","volume":"34","author":"M Dobkin de Rios","year":"2002","unstructured":"Dobkin de Rios M, Grob CS, Baker JR (2002) Hallucinogens and redemption. J Psychoactive Drugs 34(3):239\u2013248. https:\/\/doi.org\/10.1080\/02791072.2002.10399960","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"327_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/02791072.2005.10399794","volume":"37","author":"E Doering-Silveira","year":"2005","unstructured":"Doering-Silveira E, Grob CS, Dobkin de Rios M, Lopez E, Alonso LK, Tacla C et al (2005) Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs 37(2):141\u2013144. https:\/\/doi.org\/10.1080\/02791072.2005.10399794","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"327_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/shm\/hkl039","volume":"19","author":"E Dyck","year":"2006","unstructured":"Dyck E (2006) \u2018Hitting highs at rock bottom\u2019: LSD treatment for alcoholism, 1950\u20131970. Soc Hist Med 19(2):313\u2013329. https:\/\/doi.org\/10.1093\/shm\/hkl039","journal-title":"Soc Hist Med"},{"key":"327_CR20","doi-asserted-by":"publisher","unstructured":"Ermakova AO, Dunbar F, Rucker J, Johnson MW (2021) A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol. https:\/\/doi.org\/10.1177\/02698811211050543","DOI":"10.1177\/02698811211050543"},{"issue":"3","key":"327_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","volume":"111","author":"JM F\u00e1bregas","year":"2010","unstructured":"F\u00e1bregas JM, Gonz\u00e1lez D, Fondevila S, Cutchet M, Fern\u00e1ndez X, Barbosa PCR et al (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 111(3):257\u2013261. https:\/\/doi.org\/10.1016\/j.drugalcdep.2010.03.024","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"327_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths R, Johnson M (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7(3):157\u2013164. https:\/\/doi.org\/10.2174\/1874473708666150107121331","journal-title":"Curr Drug Abuse Rev"},{"issue":"9","key":"327_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881119845793","volume":"33","author":"A Garcia-Romeu","year":"2019","unstructured":"Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33(9):1088\u20131101. https:\/\/doi.org\/10.1177\/0269881119845793","journal-title":"J Psychopharmacol"},{"key":"327_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","volume":"10","author":"A Garcia-Romeu","year":"2020","unstructured":"Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW (2020) Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psych 10:955. https:\/\/doi.org\/10.3389\/fpsyt.2019.00955","journal-title":"Front Psych"},{"issue":"7","key":"327_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T et al (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513\u2013520. https:\/\/doi.org\/10.1097\/NMD.0000000000000113","journal-title":"J Nerv Ment Dis"},{"issue":"25","key":"327_CR26","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35(25):2505\u20132511. https:\/\/doi.org\/10.1016\/0024-3205(84)90436-3","journal-title":"Life Sci"},{"issue":"12","key":"327_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"issue":"1","key":"327_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/j.2326-1951.1981.tb01901.x","volume":"21","author":"L Grinspoon","year":"1981","unstructured":"Grinspoon L (1981) LSD reconsidered. Sciences 21(1):20\u201323. https:\/\/doi.org\/10.1002\/j.2326-1951.1981.tb01901.x","journal-title":"Sciences"},{"issue":"1","key":"327_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1):71\u201378. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"327_CR30","first-page":"SR15","volume":"14","author":"JH Halpern","year":"2008","unstructured":"Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit 14(8):SR15\u2013SR22","journal-title":"Med Sci Monit"},{"issue":"9","key":"327_CR31","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/add.14656","volume":"114","author":"SE Jackson","year":"2019","unstructured":"Jackson SE, Kotz D, West R, Brown J (2019) Moderators of real-world effectiveness of smoking cessation aids: a population study. Addiction 114(9):1627\u20131638. https:\/\/doi.org\/10.1111\/add.14656","journal-title":"Addiction"},{"issue":"3","key":"327_CR32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14(3):734\u2013740. https:\/\/doi.org\/10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"issue":"6","key":"327_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards W, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587","journal-title":"J Psychopharmacol"},{"issue":"11","key":"327_CR34","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992. https:\/\/doi.org\/10.1177\/0269881114548296","journal-title":"J Psychopharmacol"},{"issue":"1","key":"327_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR (2017a) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 43(1):55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"327_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/0269881116684335","volume":"31","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Johnson PS, Griffiths RR (2017b) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol 31(7):841\u2013850. https:\/\/doi.org\/10.1177\/0269881116684335","journal-title":"J Psychopharmacol"},{"key":"327_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR (2019) Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther 197:83\u2013102. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010","journal-title":"Pharmacol Ther"},{"issue":"1","key":"327_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","volume":"36","author":"A Kolodny","year":"2015","unstructured":"Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW et al (2015) The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health 36(1):559\u2013574. https:\/\/doi.org\/10.1146\/annurev-publhealth-031914-122957","journal-title":"Annu Rev Public Health"},{"issue":"7","key":"327_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen P (2012) Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 26(7):994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253","journal-title":"J Psychopharmacol"},{"issue":"10","key":"327_CR40","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1176\/ajp.123.10.1202","volume":"123","author":"AA Kurland","year":"1967","unstructured":"Kurland AA, Unger S, Shaffer JW, Savage C (1967) Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: a preliminary report. Am J Psychiatry 123(10):1202\u20131209. https:\/\/doi.org\/10.1176\/ajp.123.10.1202","journal-title":"Am J Psychiatry"},{"issue":"11","key":"327_CR41","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1177\/0269881111420188","volume":"25","author":"KA MacLean","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25(11):1453\u20131461. https:\/\/doi.org\/10.1177\/0269881111420188","journal-title":"J Psychopharmacol"},{"issue":"4","key":"327_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/02791072.1998.10399714","volume":"30","author":"M Mangini","year":"1998","unstructured":"Mangini M (1998) Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs 30(4):381\u2013418. https:\/\/doi.org\/10.1080\/02791072.1998.10399714","journal-title":"J Psychoactive Drugs"},{"key":"327_CR43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/ajp.128.6.695","volume":"128","author":"J Menninger","year":"1971","unstructured":"Menninger J (1971) Discussion of Bergman RL (1971): Navajo peyote use: its apparent safety. Am J Psychiatr 128:695\u2013699. https:\/\/doi.org\/10.1176\/ajp.128.6.695","journal-title":"Am J Psychiatr"},{"issue":"10","key":"327_CR44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jama.291.10.1238","volume":"291","author":"AH Mokdad","year":"2004","unstructured":"Mokdad AH, Marks JS, Stroup DF, Gerberding JL (2004) Actual causes of death in the United States, 2000. JAMA 291(10):1238\u20131245. https:\/\/doi.org\/10.1001\/jama.291.10.1238","journal-title":"JAMA"},{"issue":"6","key":"327_CR45","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/eurheartj\/ehn552","volume":"30","author":"S Mottillo","year":"2009","unstructured":"Mottillo S, Filion KB, B\u00e9lisle P, Joseph L, Gervais A, O'Loughlin J et al (2009) Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 30(6):718\u2013730. https:\/\/doi.org\/10.1093\/eurheartj\/ehn552","journal-title":"Eur Heart J"},{"issue":"10258","key":"327_CR46","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"CJL Murray","year":"2020","unstructured":"Murray CJL, Aravkin AY, Zheng P, Abbafati C, Abbas KM, Abbasi-Kangevari M et al (2020) Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet 396(10258):1223\u20131249. https:\/\/doi.org\/10.1016\/S0140-6736(20)30752-2","journal-title":"Lancet"},{"issue":"4","key":"327_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/a-1312-7297","volume":"54","author":"S Nayak","year":"2021","unstructured":"Nayak S, Johnson MW (2021) Psychedelics and psychotherapy. Pharmacopsychiatry 54(4):167\u2013175. https:\/\/doi.org\/10.1055\/a-1312-7297","journal-title":"Pharmacopsychiatry"},{"key":"327_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fphar.2018.00132","volume":"9","author":"EM Nielson","year":"2018","unstructured":"Nielson EM, May DG, Forcehimes AA, Bogenschutz MP (2018) The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol 9:132. https:\/\/doi.org\/10.3389\/fphar.2018.00132","journal-title":"Front Pharmacol"},{"issue":"7","key":"327_CR49","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol 32(7):756\u2013769. https:\/\/doi.org\/10.1177\/0269881118780612","journal-title":"J Psychopharmacol"},{"issue":"11","key":"327_CR50","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland AA, Unger S, Savage C, Grof S (1970) The experimental use of psychedelic (LSD) psychotherapy. J Am Med Assoc 212(11):1856\u20131863. https:\/\/doi.org\/10.1001\/jama.1970.03170240060010","journal-title":"J Am Med Assoc"},{"issue":"4","key":"327_CR51","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA et al (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655\u2013663. https:\/\/doi.org\/10.1017\/S0033291718001356","journal-title":"Psychol Med"},{"issue":"3","key":"327_CR52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/02791072.1976.10472016","volume":"8","author":"P Pascarosa","year":"1976","unstructured":"Pascarosa P, Futterman S (1976) Ethnopsychedelic therapy for alcoholics: observations in the peyote ritual of the native American church. J Psychedelic Drugs 8(3):215\u2013221. https:\/\/doi.org\/10.1080\/02791072.1976.10472016","journal-title":"J Psychedelic Drugs"},{"issue":"1","key":"327_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/dar.13348","volume":"41","author":"D Perkins","year":"2022","unstructured":"Perkins D, Opaleye ES, Simonova H, Bouso JC, T\u00f3foli LF, Galv\u00c3o-Coelho NL et al (2022) Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: results of a large international cross-sectional survey. Drug Alcohol Rev 41(1):265\u2013274. https:\/\/doi.org\/10.1111\/dar.13348","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"327_CR54","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","volume":"31","author":"VD Pisano","year":"2017","unstructured":"Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC (2017) The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol 31(5):606\u2013613. https:\/\/doi.org\/10.1177\/0269881117691453","journal-title":"J Psychopharmacol"},{"issue":"4","key":"327_CR55","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/02791072.1977.10472060","volume":"9","author":"JC Rhead","year":"1977","unstructured":"Rhead JC, Soskin RA, Turek I, Richards WA, Yensen R, Kurland AA et al (1977) Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. J Psychedelic Drugs 9(4):287\u2013300. https:\/\/doi.org\/10.1080\/02791072.1977.10472060","journal-title":"J Psychedelic Drugs"},{"key":"327_CR56","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL (2018) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 8:974. https:\/\/doi.org\/10.3389\/fphar.2017.00974","journal-title":"Front Pharmacol"},{"issue":"12","key":"327_CR57","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"issue":"3","key":"327_CR58","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1176\/ajp.130.3.329-b","volume":"130","author":"C Roy","year":"1973","unstructured":"Roy C (1973) Indian peyotists and alcohol. Am J Psychiatry 130(3):329\u2013330. https:\/\/doi.org\/10.1176\/ajp.130.3.329-b","journal-title":"Am J Psychiatry"},{"issue":"6","key":"327_CR59","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","volume":"28","author":"C Savage","year":"1973","unstructured":"Savage C, McCabe OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry 28(6):808\u2013814. https:\/\/doi.org\/10.1001\/archpsyc.1973.01750360040005","journal-title":"Arch Gen Psychiatry"},{"key":"327_CR60","volume-title":"Pihkal: a chemical love story","author":"AT Shulgin","year":"1991","unstructured":"Shulgin AT, Shulgin A (1991) Pihkal: a chemical love story. Transform Press, Berkeley"},{"key":"327_CR61","volume-title":"Tihkal: the continuation","author":"AT Shulgin","year":"1997","unstructured":"Shulgin AT, Shulgin A (1997) Tihkal: the continuation. Transform Press, Berkeley"},{"issue":"3","key":"327_CR62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.15288\/qjsa.1958.19.406","volume":"19","author":"CM Smith","year":"1958","unstructured":"Smith CM (1958) A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol 19(3):406\u2013417. https:\/\/doi.org\/10.15288\/qjsa.1958.19.406","journal-title":"Q J Stud Alcohol"},{"issue":"2","key":"327_CR63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.15288\/qjsa.1959.20.292","volume":"20","author":"CM Smith","year":"1959","unstructured":"Smith CM (1959) Some reflections on the possible therapeutic effects of the hallucinogens; with special reference to alcoholism. Q J Stud Alcohol 20(2):292\u2013301. https:\/\/doi.org\/10.15288\/qjsa.1959.20.292","journal-title":"Q J Stud Alcohol"},{"issue":"12","key":"327_CR64","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0006-3223(95)00418-1","volume":"39","author":"M Spitzer","year":"1996","unstructured":"Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar K, Heimann H et al (1996) Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry (1969) 39(12):1055\u20131057. https:\/\/doi.org\/10.1016\/0006-3223(95)00418-1","journal-title":"Biol Psychiatry (1969)"},{"issue":"2","key":"327_CR65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans: I. neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry 51(2):85\u201397. https:\/\/doi.org\/10.1001\/archpsyc.1994.03950020009001","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"327_CR66","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","volume":"4","author":"JC Strickland","year":"2021","unstructured":"Strickland JC, Garcia-Romeu A, Johnson MW (2021) Set and setting: a randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacol Transl Sci 4(2):472\u2013478. https:\/\/doi.org\/10.1021\/acsptsci.0c00187","journal-title":"ACS Pharmacol Transl Sci"},{"key":"327_CR67","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/02698811211008554","volume":"36","author":"PJ Teixeira","year":"2021","unstructured":"Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL (2021) Psychedelics and health behaviour change. J Psychopharmacol 36:12\u201319","journal-title":"J Psychopharmacol"},{"key":"327_CR68","volume-title":"The health consequences of smoking \u2013 50 years of progress: a report of the surgeon general","author":"US Department of Health and Human Services","year":"2014","unstructured":"US Department of Health and Human Services (2014) The health consequences of smoking \u2013 50 years of progress: a report of the surgeon general. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta"},{"key":"327_CR69","unstructured":"US National Library of Medicine (2021a) A double-blind trial of psilocybin-assisted treatment of alcohol dependence. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02061293. Accessed 10 Oct 2021"},{"key":"327_CR70","unstructured":"US National Library of Medicine (2021b) Psilocybin-facilitated smoking cessation treatment: a pilot study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01943994. Accessed 10 Oct 2021"},{"key":"327_CR71","unstructured":"US National Library of Medicine (2021c) Psilocybin-facilitated treatment for cocaine use. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02037126. Accessed 10 Oct 2021"},{"issue":"5","key":"327_CR72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16(5):357\u2013372. https:\/\/doi.org\/10.1016\/S0893-133X(96)00246-1","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"327_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/mpr.328","volume":"20","author":"H Wittchen","year":"2011","unstructured":"Wittchen H, Hoch E, Klotsche J, Muehlig S (2011) Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention. Int J Methods Psychiatr Res 20(1):28\u201339. https:\/\/doi.org\/10.1002\/mpr.328","journal-title":"Int J Methods Psychiatr Res"}],"container-title":["Current Topics in Behavioral Neurosciences","Disruptive Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2022_327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T16:08:09Z","timestamp":1661443689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2022_327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783031121838","9783031121845"],"references-count":73,"URL":"https:\/\/doi.org\/10.1007\/7854_2022_327","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"16 June 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}